Show simple item record

dc.contributor.advisorMathews, Kelly
dc.contributor.advisorMauro, Joseph
dc.contributor.authorDhaliwal, Sarina
dc.date.accessioned2019-11-25T21:26:49Z
dc.date.available2019-11-25T21:26:49Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10150/636250
dc.descriptionClass of 2019 Abstract, Poster, and Paperen_US
dc.description.abstractSpecific Aims: To compare sustained virological response at 12 weeks after the end of therapy (SVR12) rates of direct acting antiviral (DAA) hepatitis C therapies in patients at a specialty pharmacy to SVR12 rates from recently published literature. To identify insurance coverage rates among different insurance payer types. Subjects: Patients that were at least 18 years or older, have a diagnosis of Hepatitis C, and had at least 1 DAA fill from Avella Specialty Pharmacy. Methods: A retrospective chart review was conducted utilizing data extracted from patient profiles who have filled a prescription at Avella Specialty Pharmacy for either Epclusa, Harvoni, Mavyret, Vosevi, or Zepatier during January 2017 to March 2018. Main Results: Of the 1,738 patients extracted for the review, 712 patients had SVR12 outcomes documented. The overall SVR12 rate of patients at Avella Specialty Pharmacy was not significantly different from published literature (97% vs 97%, p=0.96). Patients with genotype 2 at Avella Specialty Pharmacy achieved a total higher SVR12 rate when compared to published literature (100% vs 96%, p<0.05). Medicare had the highest coverage rates and Medicaid had the lowest coverage rates (56% and 16%, respectively). Conclusions: Our findings show that Avella Specialty Pharmacy can help patients obtain high cost medications through their insurance while maintaining SVR12 rates similar to those published in the literature. The services provided to patients by specialty pharmacies are essential to maintain high treatment outcomes and improve coverage rates.en_US
dc.language.isoen_USen_US
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author.en_US
dc.subjectHepatitis Cen_US
dc.subjectTherapiesen_US
dc.subjectPharmacyen_US
dc.subjectPatientsen_US
dc.subjectSustained Virological Responseen_US
dc.subject.meshHepatitis Cen_US
dc.subject.meshTherapies, Investigationalen_US
dc.subject.meshPharmacyen_US
dc.subject.meshPatientsen_US
dc.titleSVR Rates of Direct-Acting Antiviral Hepatitis C Therapies in Patients at a Specialty Pharmacyen_US
dc.typetexten_US
dc.typeElectronic Reporten_US
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen_US
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en_US
refterms.dateFOA2019-11-25T21:26:50Z


Files in this item

Thumbnail
Name:
Group 22- Poster DAA Therapies ...
Size:
307.5Kb
Format:
PDF
Thumbnail
Name:
Group 22-Final Project Report ...
Size:
253.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record